Key Takeaway: Cognition Therapeutics has announced an extension of its Zervimesine program targeting dementia with Lewy bodies (DLB). The decision reflects the company's ongoing commitment to developing treatments for this challenging condition. Further details on the implications of this extension were not provided in the article.
Price reaction · baseline $1.068 (2026-02-06T16:57:00.000Z) · hit during market hours · clean, no other CGTX news in the window
day 0 close · peak
-0.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.